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Objectives: The NHS Abdominal Aortic Aneurysm Screening Programme (NAAASP), based on the Multi-
centre Aneurysm Screening Study (MASS) trial (2002), is being introduced across the UK. Recent studies
have demonstrated a decline in prevalence of abdominal aortic aneurysm (AAA). The aim of this study
was to examine the effect of this on screening workload.
Methods: A model was developed to predict screening and surgical workload for a screening centre
(Bristol e population 1,123,203). Workload was compared using data from MASS with data from the
“Early Implementers” (EI) of NAAASP.
Results: Modelling for 2011/2012 using EI data predicted signiﬁcantly fewer men diagnosed with an AAA
compared to MASS data [84 (EI) versus 198 (MASS) p < 0.0001] and fewer referrals to a vascular surgeon
for AAA repair [10 (EI) versus 30 (MASS) p ¼ 0.0002). This difference became more marked with time
(2015/16: 90 (EI) versus 212 (MASS) men diagnosed with an AAA (p < 0.0001) and 29 (EI) versus 71
(MASS) referred to a vascular surgeon (p < 0.0001)). From 2015/16 there was also a signiﬁcant reduction
in the predicted number of ultrasound scans.
Conclusions: Modelling screening activity based on contemporary epidemiological data demonstrates
a signiﬁcant reduction in workload compared to MASS data. This has implications for workforce plan-
ning, the introduction of new screening centres and the future of NAAASP.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
The efﬁcacy of screening for abdominal aortic aneurysm (AAA) in
reducing aneurysm-related mortality in men has been established
following four randomised controlled trials1e4 summarised in
a Cochrane review in2007.5 Each trial differed slightly inprotocol and
inclusion criteria. TheNationalHealthService (NHS) abdominal aortic
aneurysmscreening programme (NAAASP) currently being rolled out
across the UKwasmodelled on theMulticentre Aneurysm Screening
Study (MASS) and the economic calculationswere basedon theMASS
data.6 These indicated that AAA screening reached borderline
cost-effectiveness at four years (based on NHS thresholds of cost-
effectiveness at that time [£30,000 per QALY in 20027]), but became
signiﬁcantly more cost-effective over time.8 The UK government
approved funding for anNHSAAAscreeningprogramme(NAAASP) in
2008 and in 2009 the programme began to be rolled out acrosstions on this paper, please go
.
.J. Darwood).
ciety for Vascular Surgery. PublisheEngland. Six areas with pre-existing screening programmes became
“early implementers” of the national programme. These included
Gloucestershire (screening since 1990) and Chichester (screening
since 1988). Similar programmes have been introduced on a county-
basis in Sweden and screening is recommended for male smokers
between the ages of 65 and 75 years in the United States.
Within the NAAASP men in their 65th year are invited for
a single ultrasound scan of their abdominal aorta. Men aged over 65
years are able to self-refer for an ultrasound scan should they wish.
Men found to have an aortic diameter of less than 3 cm on their
initial screen are reassured and discharged; those with an aortic
diameter of 3e5.4 cm enter an ultrasound surveillance programme
and those with an aortic diameter of >5.4 cm are referred to
a vascular surgeon for consideration of repair of their AAA.9
In theMASS study (1997e1999) 4.9% of 65e74 year oldmenwho
underwent an ultrasound scan were found to have an abdominal
aortic aneurysm (deﬁned as aortic diameter3 cm).2 More recently
several authors have documented a lower prevalence of AAA than
this10e12 leading to concerns that the AAA screening programme
may not be cost-effective. The Gloucestershire Aneurysm Screening
Programme (GASP) reported a reduction in the prevalence of AAA
(3 cm) from 4.7% in 1990 to 1.1% in 2009 in men aged 65 years.10d by Elsevier Ltd. All rights reserved.
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in prevalence of AAA (3 cm) from3.2% in 2001 to 2.7% in 2008.11 In
2009/2010 two London units presenting year one results from the
NAAASP found a lower prevalence of AAA (3 cm) than expected,
0.8%13 and 1.9%12 respectively. In addition results from the Swedish
screening programme found a prevalence of 1.7% in 65-year old
men (between 2006 and 2009).14
The area of Bristol, Bath and Weston (UK) is in the process of
implementing a local AAA screening programme as part of NAAASP.
The aim of this study was to evaluate the predicted impact of
a reduction in AAA prevalence in the screened population on the
screening and operative workload.Methods
A model was constructed using Excel2003 (Microsoft Corps)
to estimate the effect the introduction of a local AAA screening
programme as part of NAAASP would have on the screen-detected,
incidental elective and emergency operative workloads in the three
vascular units. The model was based on a simple decision tree to
estimate the effect of a change in aortic aneurysm prevalence on
screening workload (Fig. 1). This model assumes that NAAASP
Standard Operating Procedures15 are applied and requires
screening data and local population data. The screening data for the
screening cohorts (men in 65th year) requires the following vari-
ables to be taken from existing programmes:
 Screening uptake (percentage of invited men who attend)
 Number of AAA detected (AAA prevalence)
 Number of large (>5.4 cm) AAA at initial scan (AAA size
distribution)
 Rate of growth for small (3e4.4 cm) and medium (4.5e5.4 cm)
AAA65 ye
Invited cohort 
Attended
Screened cohort 
Small AAA  Large 
Surveillance 
Medium AAA 
Self-referred 
Did not attend  
Figure 1. Screening w Proportion of men with large (>5.4 cm) aneurysms who
undergo AAA repair
 Drop out from the programme
Local population data was obtained from the Primary Care Trust
Information Management and Technology (PCT I, M & T) Consor-
tium and provided the following;
 Total population (Bristol, North Somerset and South Glouces-
tershire [BNSSG] commissioning group, NHS Bath and North
East Somerset [BaNES])
 Male population over 65 years stratiﬁed by 5 year age bands
 New 65-year-olds for each year (i.e. screening cohort)
The baseline data were from general practitioner (family
doctor) registrations in 2009, and the changes in population were
based on the latest Ofﬁce for National Statistics (ONS) projections.
The Ofﬁce for National Statistics is a UK government organisation
that runs the national census and provides a range of demo-
graphic, social and economic statistics. Current ONS UK population
projections are for each year until 2015/2016, then for 2020/2021
and 2030/2031.
Current local hospital activity data were provided by the NHS
Avon Information Management and Technology Consortium based
on codes for abdominal aortic aneurysm repair (L194, L195, L27x
and L28x) performed on men from within the screening pro-
gramme area (post code search) at each of the three vascular units
within the area. The number of self-referrals in 65-year-old men
was based on MASS data, 2% of the population in 2010, reducing to
1% in 2015 and 0% in 2020.
The output of the model using the MASS screening data were
then compared with the output using data from the “early imple-
menters” of the NHS screening programme (NAAASP) in the UK.
The rate of growth of known aneurysms was assumed to be thear old men 
Excluded
Did not attend 
Normal
AAA Referred
Operated Non-operated 
Died Survived 
orkload model.
Table 1
Screening variables for model.
MASS data (%)
(n ¼ 27,147)
Early implementers data (%)
(n ¼ 23,696)
Screening Uptake 80 80
Prevalence AAA (>3 cm)
[95% conﬁdence intervals]
4 [3.77e4.23] 1.7 [1.54e1.86]
Small AAA (3.0e4.4 cm)
as percentage of total AAA
71 82
Medium AAA (4.5e5.4 cm)
as percentage of total AAA
17 7
Large AAA (>5.4 cm) as
percentage of total AAA
12 11
Percentage AAA operated 90 77
Figure 3. Projected AAA screening related activity based on MASS data.
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available for NAAASP (Table 1).
Statistic analysis was performed using the Chi-Squared test for
signiﬁcance.
Results
Population
The total population for the screening area of Bristol, Bath and
Weston is 1,123,203 in the year 2010e2011, projected to increase to
1,382,242 by 2030/2031. Of these 77,816 are men over 65 years of
whom 5924 are new 65-year-olds eligible for screening in 2010/
2011. This is projected to increase to 111,811 men over 65 years in
2030/2031 of whom 7818 will be new 65-year-olds eligible for
screening (i.e. a 43% increase overall, 32% increase in new 65-year-
olds) (Fig. 2).
MASS trial data
The MASS screening data are summarised in Table 1, column 1.
Using these data for the Bristol and Bath population the screening
programme would detect 198 men with AAA 3 cm in 2011/2012,
increasing to 212 in 2015/2016 and 250 in 2030/2031. In the ﬁrst
year of screening (2011/2012) 46 surveillance scans would be
required (for AAA 3e5.4 cm diameter), increasing rapidly to 840 in
2015/16 and 1688 by 2030/2031 (Fig. 3).
In the ﬁrst year of screening 30 men would require referral to
a vascular surgeon for consideration of AAA repair (AAA > 5.4 cm)
increasing to 71 in 2015/2016 and 126 in 2030/2031. Using the
MASS data the projected total number of elective aneurysm repairs
(screened and non-screened) in men would slowly increase from
120 in 2011/2012 to 153 in 2015/2016 and 165 in 2030/2031 (Fig. 4).Figure 2. Projected population change in men aged 65 years and older 2010e2030.The projected numbers of emergency AAA repairs for rupture
in men after screening is introduced is projected to remain stable
(40 per annum) until 2015/2016 due to the projected total
population increase, before declining to 24 (40% decrease) by
2030/2031.
Early implementation centre data
The NAAASP “Early implementers” (EI) data are summarised in
Table 1, column 2.17 Using the EI data there would be a highly
signiﬁcant reduction in the number of men with an AAA detected
on initial screening in 2011/2012 compared to the MASS data (84
versus 198, p < 0.0001). This discrepancy becomes more
pronounced with time; in 2015/2016 there would be 90 men
diagnosed with an AAA on their initial screen (versus 212 based on
MASS data, p < 0.0001) and in 2030/2031, 106 men would be
diagnosed with an AAA on their initial screen (versus 250 using
MASS data, p < 0.0001).
There are fewer ultrasound scans (initial and surveillance)
projected using EI data (Fig. 5), although this does not reach
signiﬁcance until 2015/2016 (2011/2012: 4948 (EI) versus
4985(MASS) scans, p ¼ 0.59, 2015/2016: 5682 (EI) versus 6146
(MASS) p < 0.0001, 2030/2031: 7040 (EI) versus 7943 (MASS),
p < 0.0001).
Using the EI data in the ﬁrst year of screening (2011/2012)
signiﬁcantly fewermenwould require referral to a vascular surgeon
with an AAA > 5.4 cm on screening (10 (EI) versus 30 (MASS),
p ¼ 0.0002), in 2015/2016 twenty-nine men would require referral
(compared to 71 using MASS data p < 0.0001) and in 2030/2031
ﬁfty-ﬁve menwould require referral (compared to 126 using MASS
data, p < 0.0001).Figure 4. Projected elective AAA activity using MASS data.
Figure 5. Total number of projected ultrasound scans (screening and surveillance) for
Bristol and Bath.
Figure 7. Sensitivity analysis looking at the impact of screening uptake with error bars
showing range from 75% to 85% uptake for screening.
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on EI data would increase from 100 in 2011/2012 (compared to 120
MASS p ¼ 0.07) to 111 in 2015/2016 (compared to 153 MASS
p ¼ 0.0004) and 94 in 2030/2031 (compared to MASS 165
p < 0.0001) (Fig. 6).
The projected number of emergency AAA repairs is the same as
using the MASS data.Sensitivity analysis of screening uptake
In the MASS trial the uptake of AAA screening was 85% in the
least deprived quartile and 75% in the most deprived quartile. The
impact on predicted screen-detected AAA repair is shown in Fig. 7.Discussion
Prior to commencing screening local NHS AAA screening pro-
grammes are required to calculate screening and surgical activity
projections based on MASS data.16 Recently several studies have
reported a reduction in the prevalence of AAA, suggesting MASS
data may be historical. This reduction in AAA prevalence may be as
great as a reduction from 4.7 to 1.1% in 65-year-old men. We
compared scenarios for a local screening programme using
historical (1997e1999) MASS data and contemporary (2009e2010)
NAAASP data on AAA prevalence to model the impact on screening
and surgical workload. Using NAAASP data resulted in a signiﬁcant
reduction in the projected number of men detected with AAA and
in the number of men with a large (5.4 cm) AAA being referred for
surgery. There was a reduction in the total projected number of
elective AAA repairs compared to the MASS data, albeit an increase
compared to the workload without screening. There was alsoFigure 6. Projected elective AAA activity using early implementation data.a reduction in the total projected number of ultrasound scans
required although this was less striking and does not reach statis-
tical signiﬁcance for the ﬁrst 5 years of screening.
One possible explanation for the differences in AAA prevalence
between NAAASP and MASS is different methodology. MASS
recruited 65e74-year-old men whereas in the NAAASP 65-year-old
men are invited for screening, although men over 65 years can self-
refer, so NAAASP targets a younger population than MASS. Despite
this, the Gloucestershire Aneurysm Screening Programme has
reported a reduction in prevalence of AAA in 65-year-old men over
the last 20 years,10 suggesting the difference in the observed
prevalence between NAAASP and MASS is not solely attributable to
the older population screened in MASS. The difference in the age
group between MASS and NAAASP may also impact on aneurysm
growth and the proportion of men offered aneurysm repair. Inter-
estingly however the proportion of menwith an aneurysm>5.4 cm
undergoing surgical repair was lower in the NAAASP (younger)
group.
The second difference is that in the technique of AAA
measurement. In MASS scans were performed by ultrasonogra-
phers and themaximum aortic diameter was measured from outer-
to-outer wall of the aorta. In the NAAASP scans are performed by
trained technicians, the maximum aortic diameter is measured
from inner-to-inner wall of the aorta. Although there is a discrep-
ancy between inner-to-inner and outer-to-outer wall measure-
ments, a recent study demonstrated this difference to be in the
order of 0.27 mm18 so this is unlikely to explain all of the observed
difference in prevalence.
Previous economic analyses on which cost-effectiveness for the
NAAASP has been calculated were based on MASS data, which may
now be obsolete. The impact of a reduction in AAA prevalence has
a signiﬁcant effect on AAA screening cohorts with a reduction in
both the number of men referred for surgery and the number
entering surveillance. Cost-effectiveness calculations are complex
and there have been conﬂicting studies regarding the cost-
effectiveness of AAA screening. Whilst calculations based on the
MASS and Viborg studies have indicated AAA screening to be cost-
effective,8,19 a predictive Danish model using the MASS data
concluded AAA screening was not cost-effective.20 There was
a huge variation in the cost per QALY between these studies, which
will depend on the costs of screening (different in different coun-
tries), the proportion of AAA treated with EVAR and the cost of AAA
repair.21 A recent cost-effectiveness model suggested that in
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even with AAA prevalence rates as low as 1%.22 Cost-effectiveness
and screening workload will also be affected by other screening
variables such as screening uptake, rate of aneurysm growth and
proportion of men with AAA >5.4 cm who undergo AAA repair.
The reason for a reduction in the prevalence of AAA in 65-year-
old men may be multifactorial: smoking and hypertension have
been strongly linked with the development and expansion of
AAA.23e25 Epidemiological studies have demonstrated a reduction
in smoking-related deaths in men since 1995 in all developed
countries and in Europe since the mid-1980s.26 In the UK smoking
has been steadily declining since the 1970s, and the proportion of
men over the age of 60 who smoke has reduced from 44% in 1974 to
15% in 2009, based on Ofﬁce for National Statistics Data.27 Several
studies have shown an inverse relationship with type 2 diabetes
and prevalence and growth of AAA.25,28,29 Obesity, type 2 diabetes
and dyslipidaemia are all increasing and this may play a role in the
reduction of the prevalence of AAA.30 In addition statins have been
linked with a reduction in AAA and the increasing use of these may
also be implicated.31e33
It is possible that since the MASS study there has been an
increased use of medical imaging, speciﬁcally abdominal ultra-
sound and computerised tomography CT.34 Awareness of AAA may
also have changed and men may present earlier (<65 years) for
screening, especially those with a family history. Men with a pre-
existing diagnosis of AAA are excluded from NAAASP and so
would result in an underestimate of AAA prevalence in the
screening cohort.
This model did not demonstrate a reduction in the incidence of
ruptured AAAwith the NAAASP data compared to the MASS data. It
is not knownwhether the reduction in prevalence inmen attending
for abdominal aortic aneurysm screening is replicated in those men
who do not attend for screening and in women. This is a weakness
of the model and it may be that the prevalence of ruptured AAA
using the EI data has been overestimated.
It is important to emphasize that the data from NAAASP
include 23,696 men from the initial 6 screening centres, which
while similar to the number of men screened within the MASS
study, only represents a small sample of the overall screening
population (men aged 65 years) in the UK. It is not yet known
whether the observed reduction in AAA prevalence seen within
this cohort is a national phenomenon and therefore at this stage
the authors wish to be cautious regarding the generalisability
of the study ﬁndings. HES (Hospital Episode Statistics) data
indicate that despite the apparent observed decrease in the
prevalence of AAA the number of aortic repairs is increasing in
the UK.
In addition the model was based on local demographics, which
will vary across different regions and countries, for example the
Bristol population has a higher proportion of over 65-year-old
men than the national average. In addition attendance rates for
screening may vary in different populations, indeed rates of less
than 50% for aneurysm screening have been reported in Northern
Ireland.35
The model predicted a reduction in the number of men entering
surveillance within the AAA screening programme, however a large
and increasing number of surveillance scans were still required
over time and this did not stabilise within the timescale of the
model (20 years). Given the increase in life expectancy men with
small AAA may require repair many years in the future. In addition
they represent a population who could be targeted for improved
cardiovascular risk factor management or potential medical
management to reduce AAA expansion.
The observed reduction in prevalence of aortic aneurysms could
be regarded as an indication to consider more targeted screening ofhigher risk groups (such as smokers, those with cardiovascular risk
factors). However there is good evidence for a population screening
programme (in men) data and no similar data currently for a tar-
geted programme. The NAAASP should provide more demographic
data which could indicate whether a targeted programme should
be considered in the future if the reduction in prevalence of aortic
aneurysm is replicated across the country.
Alternatively it may be that with an increase in life expectancy
(Ofﬁce of National Statistics data indicate life expectancy for a 65-
year-old man is increasing and currently over 20 years) a second
screen should be considered, or the aortic diameter threshold for
inclusion in surveillance should be lowered (e.g. to 2.5 cm). Both of
these modiﬁcations would clearly increase the cost of the pro-
gramme signiﬁcantly and may or may not result in a reduction
aneurysm-related mortality. Data from the Gloucestershire Aneu-
rysm Screening Programme which surveilled men with an aorta
>2.5 cm found 15% developed an aortic aneurysm >5.4 cm after 10
years follow-up. There is at present no data to indicate whether the
growth rate of aneurysms is changing and how this may impact
on ideal screening intervals, which will also affect cost-
effectiveness.
In summary, early data from NAAASP report a signiﬁcantly
lower AAA prevalence than the MASS study onwhich both NAAASP
workload projections and cost-effectiveness have been calculated.
The impact of this on a new local programme in terms of absolute
numbers of ultrasound scans and AAA repairs has beenmodelled in
this paper. The reduction in the prevalence of AAA appears real; but
it remains to be seen whether these ﬁndings are replicated across
the country in all screening centres. If this is the case then the
NAAASP may require modiﬁcation, but more data from monitoring
pre-existing NAAASP centres should be available to inform these
decisions.
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